Last reviewed · How we verify
Synalar® ointment
At a glance
| Generic name | Synalar® ointment |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Vasoconstriction Study With LEO 90100 (PHASE1)
- Using an Internet Study to Improve Adherence for Psoriasis Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synalar® ointment CI brief — competitive landscape report
- Synalar® ointment updates RSS · CI watch RSS
- LEO Pharma portfolio CI